All News
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1
Dr. John Cush RheumNow ( View Tweet)
#ACR20👀🔥🔥@AliDuarteMD Population epi revealed:
⭐️Markedly increased SLE incidence
⭐️Drastically increased SLE prevalence
Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk
Yu (Ray) Zuo RayZuoMD ( View Tweet)
UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI
Dr. Rachel Tate uptoTate ( View Tweet)
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary
Peter Nash drpnash ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Dr. Rachel Tate uptoTate ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
This convinces me! #TNF inhibitors vs #JAKI
great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
Dr. Antoni Chan synovialjoints ( View Tweet)
Important study helping dissect the JAK-IFN axis I believe - we need to be cautious in attacking this axis as anifrolumab has >2x Zoster of JAKi's- we need to read the tea leaves from IEIs and COVID-19 #ACR20 @JYazdanyMD @Lupusdoc @casanova_lab @cannalab1 https://t.co/scI13jwFZd
Leonard Calabrese LCalabreseDO ( View Tweet)
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
Eric Dein ejdein1 ( View Tweet)
The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow
Eric Dein ejdein1 ( View Tweet)
Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
Eric Dein ejdein1 ( View Tweet)
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest
Robert B Chao, MD doctorRBC ( View Tweet)
#GREATDEBATE Dr. Weinblatt won - but based on the limited # people polled d/t difficulties with website #ACR20 @RheumNow
k dao KDAO2011 ( View Tweet)
The Great Debate results! https://t.co/tJk0yIRqfK
Dr. Rachel Tate uptoTate ( View Tweet)
